Elevance raises 2026 outlook to at least $29 a share as Medicare Advantage enrollment falls
Elevance Health's benefit expense ratio improved to 90.6% in the third quarter, and it now expects 2026 adjusted EPS of at least $29. Medicare Advantage membership fell 15.5% from a year earlier to 1.9 million.

Elevance Health's Medicare Advantage book has shrunk over the past year, and its services arm earned more than twice as much as its health plans in the quarter.
The Indianapolis-based insurer said Oct. 21 that it raised its 2026 adjusted earnings guidance to at least $29.00 a share after a third quarter in which its benefit expense ratio improved 70 basis points to 90.6%, according to its earnings release. It also raised GAAP guidance to at least $22.00 a share and its operating cash flow outlook to at least $6.5 billion.
Why it matters: Elevance credited better results in Medicare Advantage and individual ACA plans for the lower ratio, even as Medicare Advantage enrollment fell 15.5% from a year earlier. The company also set a marker for next year: at least 12% growth in adjusted EPS in 2027, measured from a baseline of at least $26.75.
Operating revenue rose 0.7% to $50.4 billion. Diluted earnings were $6.27 a share, and adjusted diluted earnings were $6.99, up from $6.03 a year earlier. The company said results included a net non-operating benefit of $1.85 a share; net investment income rose to $1.04 billion from $625 million.
Its adjusted operating expense ratio rose 90 basis points to 11.3%, which Elevance attributed mainly to one-time spending on capabilities, along with spending on growth and quality initiatives.
Medical membership was about 44.9 million at Sept. 30, down 487,000 from a year earlier. Medicare Advantage enrollment fell to 1.898 million from 2.245 million, Medicaid declined 4.9% to 8.22 million, and employer group risk-based membership fell 6.9% to 3.366 million, according to the company's membership table. Commercial fee-based membership grew 2.2% to 27.6 million. Individual membership was 1.348 million, roughly flat with a year earlier and up 2.4% from June 30.
Revenue in the Health Benefits segment rose 3% to $43.4 billion on higher premium yields and service fees, the company said. The segment's operating gain fell to $0.4 billion from $0.6 billion, which Elevance attributed to targeted investments, partly offset by the improved benefit expense ratio.
Carelon carries more of the load
Carelon, the company's services and pharmacy unit, grew operating revenue 5% to $19.3 billion. Its operating gain rose 17% to $0.9 billion, more than double the Health Benefits segment's, which Elevance attributed to Carelon Services' risk-based offerings and better profitability in specialty pharmacy.
The CMS accrual and 2027
The full-year GAAP outlook includes a $4.28-a-share accrual for what Elevance called its current best estimate of potential exposure tied to some past Medicare Advantage risk adjustment data, related to a CMS notice dated Feb. 27, 2026. The company recorded $935 million for that item in the first nine months of the year. It is excluded from adjusted earnings.
The 2027 target starts from a lower number than this year's guidance. Elevance said the $26.75 baseline leaves out non-recurring net investment income, other non-operating items and targeted one-time investments. Gail Boudreaux, president and chief executive, said in the release that the company remains confident it can deliver the 12% growth from that baseline.
The release did not give a 2027 outlook for membership. Elevance's next dividend, $1.72 a share, is payable Dec. 18.



